NASDAQ:DRIO DarioHealth (DRIO) Stock Price, News & Analysis → Only a fool would buy Nvidia today… (From Porter & Company) (Ad) Free DRIO Stock Alerts $1.46 -0.06 (-3.93%) (As of 01:34 PM ET) Add Compare Share Share Today's Range$1.45▼$1.6650-Day Range$1.40▼$2.5552-Week Range$0.68▼$4.58Volume120,944 shsAverage Volume134,638 shsMarket Capitalization$39.75 millionP/E RatioN/ADividend YieldN/APrice Target$6.03 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get DarioHealth alerts: Email Address DarioHealth MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside313.2% Upside$6.03 Price TargetShort InterestBearish4.92% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.72Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.14) to ($2.25) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.41 out of 5 starsMedical Sector820th out of 938 stocksSurgical & Medical Instruments Industry87th out of 97 stocks 3.5 Analyst's Opinion Consensus RatingDarioHealth has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.03, DarioHealth has a forecasted upside of 313.2% from its current price of $1.46.Amount of Analyst CoverageDarioHealth has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted4.92% of the outstanding shares of DarioHealth have been sold short.Short Interest Ratio / Days to CoverDarioHealth has a short interest ratio ("days to cover") of 10.2, which indicates bearish sentiment.Change versus previous monthShort interest in DarioHealth has recently increased by 20.72%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldDarioHealth does not currently pay a dividend.Dividend GrowthDarioHealth does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DRIO. Previous Next 2.6 News and Social Media Coverage News SentimentDarioHealth has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for DarioHealth this week, compared to 1 article on an average week.Search InterestOnly 6 people have searched for DRIO on MarketBeat in the last 30 days. This is a decrease of -68% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added DarioHealth to their MarketBeat watchlist in the last 30 days. This is a decrease of -14% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DarioHealth insiders have not sold or bought any company stock.Percentage Held by Insiders10.10% of the stock of DarioHealth is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 33.39% of the stock of DarioHealth is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for DarioHealth are expected to decrease in the coming year, from ($2.14) to ($2.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DarioHealth is -1.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of DarioHealth is -1.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDarioHealth has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaTop Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.Just click here for instant access to the #1 Coin for 2024. About DarioHealth Stock (NASDAQ:DRIO)DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its user-centric multi-chronic condition digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Move to address most common MSK conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.Read More DRIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DRIO Stock News HeadlinesMarch 28, 2024 | finanznachrichten.deDarioHealth Corp.: DarioHealth Reports Fourth Quarter and Full-Year 2023 Financial and Operating ResultsMarch 28, 2024 | markets.businessinsider.comDarioHealth earnings preview: what to expectMarch 28, 2024 | Crypto 101 Media (Ad)Top Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.March 28, 2024 | investorplace.comDRIO Stock Earnings: DarioHealth Beats EPS, Beats Revenue for Q4 2023March 28, 2024 | finance.yahoo.comDarioHealth Reports Fourth Quarter and Full-Year 2023 Financial and Operating ResultsMarch 26, 2024 | americanbankingnews.comDarioHealth (DRIO) to Release Earnings on ThursdayMarch 21, 2024 | prnewswire.comDARIOHEALTH TO REPORT FOURTH QUARTER 2023 RESULTS ON THURSDAY, MARCH 28THMarch 15, 2024 | finance.yahoo.comDRIO Apr 2024 5.000 putMarch 28, 2024 | Crypto 101 Media (Ad)Top Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.March 12, 2024 | prnewswire.comNew Research from Dario Demonstrates Ability to Deliver Improved Health Outcomes with Integrated Solution for Members Managing Weight and Blood Glucose with or without GLP-1 MedicationsMarch 7, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: DarioHealth (DRIO), United Therapeutics (UTHR)February 28, 2024 | prnewswire.comDARIOHEALTH TO PARTICIPATE IN THE COWEN 43RD ANNUAL HEALTHCARE CONFERENCEFebruary 28, 2024 | prnewswire.comDARIOHEALTH TO PARTICIPATE IN THE COWEN 43RD ANNUAL HEALTHCARE CONFERENCEFebruary 21, 2024 | ca.finance.yahoo.comDarioHealth Corp. (DRIO)February 21, 2024 | tmcnet.comDario acquires Twill creating one of the most comprehensive digital health platform across the most prevalent chronic conditionsFebruary 21, 2024 | msn.comDario buys Twill to create digital health platform across most prevalent chronic conditionsFebruary 21, 2024 | prnewswire.comDario acquires Twill creating one of the most comprehensive digital health platform across the most prevalent chronic conditionsFebruary 6, 2024 | benzinga.comDarioHealth Stock (NASDAQ:DRIO), Short Interest ReportJanuary 18, 2024 | msn.comCano Health, DarioHealth among healthcare moversJanuary 11, 2024 | finance.yahoo.comDarioHealth (NASDAQ:DRIO) shareholders are up 38% this past week, but still in the red over the last five yearsJanuary 11, 2024 | finance.yahoo.comRegional Union Selects Dario's Cardiometabolic Solution for Diabetes, Hypertension, Weight Management and GLP-1 SupportDecember 5, 2023 | finance.yahoo.comNational Employer Selects Dario Cardiometabolic and GLP-1 Solutions to Improve Employee HealthDecember 3, 2023 | finance.yahoo.comIs It Too Late To Consider Buying DarioHealth Corp. (NASDAQ:DRIO)?November 27, 2023 | msn.comDario secures contracts for cardiometabolic solutionNovember 27, 2023 | finance.yahoo.comDario Contracts with New Employer for Cardiometabolic SolutionNovember 21, 2023 | finance.yahoo.comNew Research Sheds Light on Mediators of Improved Outcomes in Dario UsersNovember 13, 2023 | finance.yahoo.comDario Publishes New Research Demonstrating that Dario Users That Increased Physical Activity Can Maintain Reduced Blood GlucoseSee More Headlines Receive DRIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DarioHealth and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today3/28/2024Next Earnings (Confirmed)3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:DRIO CUSIPN/A CIK1533998 Webwww.mydario.com Phone(833) 914-3796Fax972-4770-4059Employees241Year Founded2011Price Target and Rating Average Stock Price Target$6.03 High Stock Price Target$8.00 Low Stock Price Target$4.10 Potential Upside/Downside+277.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-62,190,000.00 Net Margins-136.37% Pretax Margin-245.30% Return on Equity-43.03% Return on Assets-28.49% Debt Debt-to-Equity Ratio0.43 Current Ratio6.93 Quick Ratio6.26 Sales & Book Value Annual Sales$27.66 million Price / Sales1.57 Cash FlowN/A Price / Cash FlowN/A Book Value$3.12 per share Price / Book0.51Miscellaneous Outstanding Shares27,220,000Free Float24,466,000Market Cap$43.55 million OptionableOptionable Beta1.70 Social Links 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Erez Raphael (Age 51)CEO & Director Comp: $978.76kMr. Richard A. Anderson (Age 55)President Comp: $998.42kMr. Zvi Ben David (Age 63)CFO, Treasurer & Secretary Comp: $429.05kDov OppenheimCo-Founder & Production ChiefMr. Tomer Ben-Kiki (Age 53)Chief Operating Officer Josh FischerSenior Vice President of Operations & ComplianceClaudia LeviContent & Communications ManagerMary MooneyVice President of MarketingLimor DreznerChief People OfficerMr. Jean Christophe MuylHead of Commercialization North AmericaMore ExecutivesKey CompetitorsSeaStar MedicalNASDAQ:ICUDaxorNASDAQ:DXRLENSARNASDAQ:LNSRModular MedicalNASDAQ:MODDLucid DiagnosticsNASDAQ:LUCDView All CompetitorsInstitutional OwnershipVanguard Group Inc.Bought 61,034 shares on 3/11/2024Ownership: 1.334%Goldman Sachs Group Inc.Bought 30,882 shares on 3/1/2024Ownership: 0.387%Clarity Capital Partners LLCBought 170,426 shares on 2/20/2024Ownership: 0.626%Vanguard Group Inc.Bought 61,034 shares on 2/15/2024Ownership: 1.334%Citadel Advisors LLCSold 1,800 shares on 2/15/2024Ownership: 0.000%View All Institutional Transactions DRIO Stock Analysis - Frequently Asked Questions Should I buy or sell DarioHealth stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DarioHealth in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DRIO shares. View DRIO analyst ratings or view top-rated stocks. What is DarioHealth's stock price target for 2024? 2 equities research analysts have issued twelve-month target prices for DarioHealth's shares. Their DRIO share price targets range from $4.10 to $8.00. On average, they predict the company's stock price to reach $6.03 in the next twelve months. This suggests a possible upside of 313.2% from the stock's current price. View analysts price targets for DRIO or view top-rated stocks among Wall Street analysts. How have DRIO shares performed in 2024? DarioHealth's stock was trading at $1.72 at the start of the year. Since then, DRIO stock has decreased by 15.1% and is now trading at $1.4603. View the best growth stocks for 2024 here. When is DarioHealth's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024. View our DRIO earnings forecast. How were DarioHealth's earnings last quarter? DarioHealth Corp. (NASDAQ:DRIO) announced its quarterly earnings results on Monday, November, 15th. The company reported ($1.18) earnings per share for the quarter, missing the consensus estimate of ($0.94) by $0.24. The company had revenue of $5.63 million for the quarter, compared to the consensus estimate of $5.95 million. DarioHealth had a negative trailing twelve-month return on equity of 43.03% and a negative net margin of 136.37%. During the same period in the prior year, the company posted ($0.71) EPS. What other stocks do shareholders of DarioHealth own? Based on aggregate information from My MarketBeat watchlists, some companies that other DarioHealth investors own include Aeterna Zentaris (AEZS), Vascular Biogenics (VBLT), Nano Dimension (NNDM), Pluristem Therapeutics (PSTI), NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), ADMA Biologics (ADMA) and Avadel Pharmaceuticals (AVDL). Who are DarioHealth's major shareholders? DarioHealth's stock is owned by a variety of institutional and retail investors. Top institutional investors include Nantahala Capital Management LLC (8.58%), Appian Way Asset Management LP (4.86%), Clal Insurance Enterprises Holdings Ltd (3.22%), Vanguard Group Inc. (1.33%), Vanguard Group Inc. (1.33%) and Clarity Capital Partners LLC (0.63%). Insiders that own company stock include Dennis M Mcgrath, Dror Bacher, Erez Raphael and Oded Cohen. View institutional ownership trends. How do I buy shares of DarioHealth? Shares of DRIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does DarioHealth have any subsidiaries? The following companies are subsidiares of DarioHealth: Labstyle Innovation Ltd., PsyInnovations Inc., PsyInnovations India Private Limited., Upright Technologies Inc., and Upright Technologies Ltd..Read More This page (NASDAQ:DRIO) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceFed launches fourth dollar overhaulStansberry ResearchThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DarioHealth Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.